转移性肾细胞癌的管理——综述
Management of metastatic renal cell carcinoma - mini review.
作者信息
Bharthuar Anubha, Pandey Himanshu, Sood Swapan
机构信息
Department of Medical Oncology and Hematology; Department of Urology, Patel Cancer and Superspeciality Hospital, Jalandhar City, Punjab, INDIA.
出版信息
J Kidney Cancer VHL. 2015 May 5;2(2):75-83. doi: 10.15586/jkcvhl.2015.28. eCollection 2015.
Abstract
The management of metastatic renal cell carcinoma (mRCC) has evolved considerably in the last decade. A number of different systemic molecular targeted agents that have been recently approved have improved the survival of patients with mRCC. This mini-review focuses on the implementation of multi-modality therapy in the management of mRCC and the approved indications of the various available novel agents. These novel agents have expanded our armamentarium and improved clinical outcomes of this challenging disease that has considerable biological heterogeneity and clinical variability.
摘要
在过去十年中，转移性肾细胞癌（mRCC）的治疗有了显著进展。最近批准的多种不同的全身性分子靶向药物提高了mRCC患者的生存率。本综述聚焦于多模态治疗在mRCC管理中的应用以及各种可用新型药物的获批适应症。这些新型药物扩充了我们的治疗手段，改善了这种具有相当大生物学异质性和临床变异性的挑战性疾病的临床结局。
相似文献
1
Management of metastatic renal cell carcinoma - mini review.转移性肾细胞癌的管理——综述
J Kidney Cancer VHL. 2015 May 5;2(2):75-83. doi: 10.15586/jkcvhl.2015.28. eCollection 2015.
2
Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.转移性肾细胞癌的现行全身治疗 - 一线和二线治疗。
Curr Opin Support Palliat Care. 2011 Sep;5(3):211-21. doi: 10.1097/SPC.0b013e3283490418.
3
Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的系统治疗的测序和联合应用。
Eur Urol Oncol. 2019 Sep;2(5):505-514. doi: 10.1016/j.euo.2019.06.022. Epub 2019 Aug 1.
4
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.原发灶不明的癌（CUP）合并转移性肾细胞癌（mRCC）组织学和免疫组织化学特征（CUP-mRCC）：接受靶向治疗的连续患者的结果和文献复习。
Clin Genitourin Cancer. 2019 Feb;17(1):e32-e37. doi: 10.1016/j.clgc.2018.08.005. Epub 2018 Aug 28.
5
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.分子亚型提高国际转移性肾细胞癌数据库联盟预后模型的预后价值。
Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20.
6
Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.一线治疗之后转移性肾细胞癌全身治疗的优化
Urol Oncol. 2015 Dec;33(12):538-45. doi: 10.1016/j.urolonc.2015.08.007. Epub 2015 Oct 9.
7
Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma.肾细胞癌的免疫治疗靶点与疗法
Immunotargets Ther. 2020 Nov 13;9:273-288. doi: 10.2147/ITT.S240889. eCollection 2020.
8
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.晚期和转移性肾细胞癌的外科治疗：多学科方法
Front Oncol. 2017 May 31;7:107. doi: 10.3389/fonc.2017.00107. eCollection 2017.
9
Advances in treatment of metastatic renal cell carcinoma.转移性肾细胞癌的治疗进展
Curr Opin Urol. 2016 Sep;26(5):439-46. doi: 10.1097/MOU.0000000000000319.
10
Emerging therapeutics in refractory renal cell carcinoma.难治性肾细胞癌的新兴治疗方法。
Expert Opin Pharmacother. 2016 Jun;17(9):1225-32. doi: 10.1080/14656566.2016.1182987. Epub 2016 May 23.
引用本文的文献
1
MiR-501-3p/SPC24 axis affects cell proliferation, migration, invasion, apoptosis, and prognosis in renal cell carcinoma.微小RNA-501-3p/纺锤体组装蛋白24轴影响肾细胞癌的细胞增殖、迁移、侵袭、凋亡及预后。
Braz J Med Biol Res. 2025 Feb 3;58:e13507. doi: 10.1590/1414-431X2024e13507. eCollection 2025.
2
Small Bowel Perforation Due to Renal Carcinoma Metastasis: A Comprehensive Case Study and Literature Review.肾癌转移导致小肠穿孔：一项综合病例研究及文献综述
Diagnostics (Basel). 2024 Apr 3;14(7):761. doi: 10.3390/diagnostics14070761.
3
TGF‑β1 affects the renal cancer miRNome and regulates tumor cells proliferation.TGF-β1 影响肾癌的 miRNA 组，并调节肿瘤细胞的增殖。
Int J Mol Med. 2022 Apr;49(4). doi: 10.3892/ijmm.2022.5108. Epub 2022 Feb 18.
4
Tumor suppressor microRNA-136-5p regulates the cellular function of renal cell carcinoma.肿瘤抑制性微小RNA-136-5p调节肾细胞癌的细胞功能。
Oncol Lett. 2018 Apr;15(4):5995-6002. doi: 10.3892/ol.2018.8081. Epub 2018 Feb 16.
5
Solitary parotid metastasis 8 years after a nephrectomy for renal cell carcinoma.
J Community Hosp Intern Med Perspect. 2016 Sep 7;6(4):31950. doi: 10.3402/jchimp.v6.31950. eCollection 2016.
本文引用的文献
1
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.高剂量阿地白介素“选择”试验：一项前瞻性验证转移性肾细胞癌患者治疗反应预测模型的试验。
Clin Cancer Res. 2015 Feb 1;21(3):561-8. doi: 10.1158/1078-0432.CCR-14-1520. Epub 2014 Nov 25.
2
Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.依维莫司与唑来膦酸用于肾细胞癌骨转移患者：一项随机一线II期试验
Clin Genitourin Cancer. 2015 Feb;13(1):50-8. doi: 10.1016/j.clgc.2014.07.002. Epub 2014 Jul 15.
3
Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.细胞减灭性肾切除术治疗肾细胞癌同步转移患者：来自国际转移性肾细胞癌数据库联盟的结果。
Eur Urol. 2014 Oct;66(4):704-10. doi: 10.1016/j.eururo.2014.05.034. Epub 2014 Jun 13.
4
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.阿昔替尼对比索拉非尼用于晚期肾细胞癌：一项随机 III 期临床试验中按既往治疗的亚组分析。
Br J Cancer. 2014 Jun 10;110(12):2821-8. doi: 10.1038/bjc.2014.244. Epub 2014 May 13.
5
Role of metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.在靶向治疗时代，转移灶切除术对转移性肾细胞癌的作用。
World J Urol. 2014 Jun;32(3):631-42. doi: 10.1007/s00345-014-1293-6. Epub 2014 Apr 18.
6
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study.随机、对照、双盲、交叉试验评估转移性肾细胞癌患者对帕唑帕尼与舒尼替尼的治疗偏好：PISCES 研究。
J Clin Oncol. 2014 May 10;32(14):1412-8. doi: 10.1200/JCO.2013.50.8267. Epub 2014 Mar 31.
7
Renal medullary carcinoma response to chemotherapy: a referral center experience in Brazil.肾髓质癌对化疗的反应：巴西一家转诊中心的经验
Rare Tumors. 2013 Aug 20;5(3):e44. doi: 10.4081/rt.2013.e44. eCollection 2013.
8
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.帕唑帕尼对比舒尼替尼用于转移性肾细胞癌。
N Engl J Med. 2013 Aug 22;369(8):722-31. doi: 10.1056/NEJMoa1303989.
9
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.国际转移性肾细胞癌数据库联盟预后模型的外部验证及与其他模型的比较：一项基于人群的研究。
Lancet Oncol. 2013 Feb;14(2):141-8. doi: 10.1016/S1470-2045(12)70559-4. Epub 2013 Jan 9.
10
The role of metastasectomy in renal cell carcinoma in the era of targeted therapy.转移性肾细胞癌在靶向治疗时代中的作用。
Curr Urol Rep. 2013 Feb;14(1):19-25. doi: 10.1007/s11934-012-0293-6.
Zotero 插件